Do you want to read an article? Please log in or register.
18F-Fluorodeoxyglucose Positron Emission Tomography for Estimating Outcomes After Initial Treatment for Metastatic Breast Cancer: A Nonrandomized Clinical Cohort Trial
Breast Cancer
Related content
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
COMMENTED
Breast Cancer
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
★ 3
Recommended and commented by
Dr Andreas Müller, Faculty Member
J Natl Cancer Inst
Tarantino P, Lee D, Foldi J, Soulos PR, Gross CP, O'Meara T, Grinda T, Morganti S, Waks AG, Winer EP, Lin NU, Krop IE, Tolaney SM, Sammons S, Lustberg M
doi: 10.1093/jnci/djaf220
SPECIAL REPORT
Breast Cancer
Managing Side Effects in Breast Cancer Treatment
Breast Cancer
Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group
Lancet Oncol
Jensen MB, Torpe E, Teunissen Z, Taarnhøj G, Brix E, Knoop A, Yammeni S, Donskov F, Ejlertsen B
doi: 10.1016/S1470-2045(25)00085-3
Gastrointestinal Cancer
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)
Eur J Cancer
Weiss L, Stintzing S, Modest DP, Stahler A, von Weikersthal LF, Reinacher-Schick A, Decker T, Probst V, Heinrich K, Schwaner I, Kaiser F, Pihusch R, Fuchs M, Held S, Alig A, Gruenberger B, Prager GW, Tougeron D, Taieb J, Heinemann V
doi: 10.1016/j.ejca.2025.116105
Breast Cancer
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial
JAMA Oncol
Fasching PA, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, Im SA, Martin M, Xu B, Loi S, Barrios C, Untch M, Moroose R, Visco F, Hortobagyi GN, Slamon DJ, Fresco R, Zarate JP, Li Z, Waters S, Hurvitz SA
doi: 10.1001/jamaoncol.2025.3700
Genitourinary Cancer
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304)
Ann Oncol
Lin HM, Scheinberg T, Portman N, Kim RMN, Mellor R, Hunyh K, Faulkner AN, Mellett NA, Davis ID, Martin A, Sullivan D, Joshua A, McJannett M, Subhash V, Yip S, Azad AA, Marschner IC, North SA, McDermott RS, Chi KN, Stockler MR, Sweeney CJ, Meikle PJ, Horvath LG
doi: 10.1016/j.annonc.2025.05.529
Gastrointestinal Cancer
Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study
ESMO Open
Moik F, Huemer F, Doleschal B, Taghizadeh H, Reimann P, Kostmann SM, Wagner L, Abdel Hamid M, Zimmer KC, Suppé SA, Bachleitner C, Schaberl-Moser R, Amann A, Wolf D, Greil R, Jost PJ, Winder T, Rumpold H, Weiss L, Gerger A, Seeber A, Riedl JM
doi: 10.1016/j.esmoop.2026.106907
Breast Cancer
Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort
Eur J Cancer
Bouteiller F, Gourgou S, Bringuier M, Galvin A, Mailliez A, Bertrand N, Hung M, Frenel JS, Massard V, Bachelot T, Pflumio C, Gonçalves A, Levy C, Bosquet L, Jacot W, Delaloge S, Grinda T, Bellera C
doi: 10.1016/j.ejca.2025.116166